Drug Details

General Information of the Drug (ID: DR0813)
Name
hu14.18-IL2 immunicytokine
Disease Melanoma [ICD-11: 2C30] Phase 2 [1]
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          Resveratrol      Gnetum parvifolium     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Molecule(s)
                    Regulation		 Up-regulation Expression GD2  Molecule Info 
Pathway MAP
                    In-vitro Model NXS2 Neuroblastoma Rattus norvegicus
                    In-vivo Model NXS2 tumors were induced in A/J mice by injecting 2*106 cells in 100 mcL PBS subcutaneously on the left flank proximal to the spleen.
                    Experimental
                    Result(s)		 RV in combination with IC provided an enhanced anti-tumor treatment in preclinical model as it lowered the tumor burden and increased survival.
Target and Pathway
Target(s) Interleukin 2 receptor alpha (IL2RA)  Molecule Info  [3]
Interleukin 2 receptor beta (IL2RB)  Molecule Info  [3]
Interleukin 2 receptor gamma (IL2RG)  Molecule Info  [3]
KEGG Pathway Cytokine-cytokine receptor interaction Click to Show/Hide
2 Endocytosis
3 PI3K-Akt signaling pathway
4 Jak-STAT signaling pathway
5 Hematopoietic cell lineage
6 Measles
7 HTLV-I infection
8 Transcriptional misregulation in cancer
NetPath Pathway IL5 Signaling Pathway Click to Show/Hide
2 TCR Signaling Pathway
3 IL2 Signaling Pathway
4 TNFalpha Signaling Pathway
5 Leptin Signaling Pathway
Panther Pathway Interleukin signaling pathway Click to Show/Hide
Pathway Interaction Database IL12-mediated signaling events Click to Show/Hide
2 Calcineurin-regulated NFAT-dependent transcription in lymphocytes
3 Arf6 trafficking events
4 SHP2 signaling
5 IL2-mediated signaling events
6 IL2 signaling events mediated by PI3K
7 IL2 signaling events mediated by STAT5
8 Calcium signaling in the CD4+ TCR pathway
9 Downstream signaling in na&#xef
10
11 IL12 signaling mediated by STAT4
Reactome GPVI-mediated activation cascade Click to Show/Hide
2 G beta:gamma signalling through PI3Kgamma
3 Interleukin-2 signaling
4 RAF/MAP kinase cascade
5 Interleukin receptor SHC signaling
WikiPathways IL-2 Signaling Pathway Click to Show/Hide
2 Inflammatory Response Pathway
3 Interleukin-2 signaling
4 Allograft Rejection
5 TSLP Signaling Pathway
6 IL-7 Signaling Pathway
7 Interleukin-3, 5 and GM-CSF signaling
References
Reference 1 ClinicalTrials.gov (NCT00590824) Pilot hu14.18-IL2 in Resectable Recurrent Stage III or Stage IV Melanoma
Reference 2 The anti-tumor effect of resveratrol alone or in combination with immunotherapy in a neuroblastoma model. Cancer Immunol Immunother. 2011 May;60(5):731-8.
Reference 3 Immunogenicity of the hu14.18-IL2 immunocytokine molecule in adults with melanoma and children with neuroblastoma. Clin Cancer Res. 2009 Sep 15;15(18):5923-30.
 Download Picture         KEGG Link